Recruiting PHASE2 INTERVENTIONAL 1-arm NCT07017829

GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

A Phase II Trial of GT103 in Combination With Pembrolizumab in STK11 Mutant Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Roswell Park Cancer Institute

Conditions Advanced Lung Non-Small Cell Carcinoma Metastatic Lung Non-Small Cell Carcinoma Stage III Lung Cancer AJCC v8 Stage IV Lung Cancer AJCC v8

Interventions Anti-CFH Monoclonal Antibody GT103 Biopsy Procedure Biospecimen Collection Computed Tomography Echocardiography Test Magnetic Resonance Imaging Pembrolizumab

Updated 4 times since 2025 Last updated: Mar 9, 2026 Started: Apr 1, 2026 Primary completion: Dec 1, 2028 Completion: Dec 1, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Advanced Lung Non-Small Cell Carcinoma and Metastatic Lung Non-Small Cell Carcinoma, this trial is actively recruiting participants. The trial is conducted by Roswell Park Cancer Institute and has accumulated 4 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE2
Jan 2026 — Mar 2026 [monthly]

Recruiting PHASE2
Sep 2025 — Jan 2026 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jul 2025 — Sep 2025 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Roswell Park Cancer Institute

Data source: Roswell Park Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Buffalo, United States